Urine Omics Predicting IO Therapy Responses in mRCC Patients — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Urine Omics Predicting IO Therapy Responses in mRCC Patients — Stella

Recruiting

Back to Metastatic Renal Cell Carcinoma trials

Trial locations(1 site)

Taiwan

National Taiwan University Hospital, Taipei

Key details

Sponsor

National Taiwan University Hospital

Enrollment target

~400 participants

Started

January 2021

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

20 Years and older

Last updated January 2022

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov